Neal Rosen

Neal Rosen

UNVERIFIED PROFILE

Are you Neal Rosen?   Register this Author

Register author
Neal Rosen

Neal Rosen

Publications by authors named "Neal Rosen"

Are you Neal Rosen?   Register this Author

100Publications

4045Reads

17Profile Views

The Polycomb Repressor Complex 1 Drives Double-Negative Prostate Cancer Metastasis by Coordinating Stemness and Immune Suppression.

Cancer Cell 2019 Aug 18;36(2):139-155.e10. Epub 2019 Jul 18.

Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Unit 1906, PO Box 301429, Houston, TX 77054/77030-1429, USA; Department of Genitourinary Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2019.06.009DOI Listing
August 2019

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.

J Thorac Oncol 2019 May 1;14(5):802-815. Epub 2019 Mar 1.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.12.038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486868PMC
May 2019

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway.

Cancer Cell 2018 12;34(6):893-905.e8

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA; Breast Medicine Service, Department of Medicine, MSKCC, New York, NY 10065, USA; Weill-Cornell Medical College, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108183052
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2018.11.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294301PMC
December 2018

Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer.

Cancer Cell 2018 01;33(1):125-136.e3

Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Departments of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2017.12.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765991PMC
January 2018

A Braf kinase-inactive mutant induces lung adenocarcinoma.

Nature 2017 08 2;548(7666):239-243. Epub 2017 Aug 2.

Experimental Oncology, Molecular Oncology Programme, Centro Nacional de Investigaciones Oncológicas (CNIO), 28029 Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature23297DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648056PMC
August 2017

Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma.

J Invest Dermatol 2017 05 28;137(5):1135-1143. Epub 2017 Jan 28.

Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2017.01.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392423PMC
May 2017

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.

Nature 2016 06 18;534(7606):272-6. Epub 2016 May 18.

Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, California 94158, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nature17963
Publisher Site
http://dx.doi.org/10.1038/nature17963DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902179PMC
June 2016

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism.

Science 2016 Feb 14;351(6273):604-8. Epub 2016 Jan 14.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.aad6204DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4955282PMC
February 2016

Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.

J Clin Oncol 2015 Dec 31;33(34):4099-105. Epub 2015 Aug 31.

Rachel N. Grisham, Brooke E. Sylvester, Helen Won, Deborah DeLair, Zhan Yao, Ronglai Shen, Fanny Dao, Faina Bogomolniy, Vicky Makker, Evis Sala, Tara E. Soumerai, David M. Hyman, Douglas A. Levine, Neal Rosen, Michael F. Berger, David R. Spriggs, Carol A. Aghajanian, David B. Solit, and Gopa Iyer, Memorial Sloan Kettering Cancer Center; Rachel N. Grisham, Gregory McDermott, Vicky Makker, David M. Hyman, Neal Rosen, Michael F. Berger, David R. Spriggs, Carol A. Aghajanian, David B. Solit, and Gopa Iyer, Weill Cornell Medical College; Ricardo Ramirez, Graduate School of Medical Sciences; Nicholas D. Socci and Agnes Viale, Michael F. Berger, and David B. Solit, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, New York, NY; David M. Gershenson, University of Texas MD Anderson Cancer Center, Houston, TX; and John Farley, St Joseph's Hospital and Medical Center, Phoenix, AZ.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/33/34/4099.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.62.4726
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.62.4726DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669594PMC
December 2015

Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.

N Engl J Med 2015 Oct 9;373(18):1733-47. Epub 2015 Sep 9.

From the Institute of Hematology, Department of Medicine, and Centro di Ricerca Emato-Oncologico (CREO), University of Perugia, and Ospedale Santa Maria della Misericordia, Perugia (E.T., L.D.C., F.F., S.A., M.C., M.P.M., B.F.), the Department of Experimental, Diagnostic, and Specialty Medicine, Units of Hematology and Hematopathology, Bologna University School of Medicine, Bologna (A.B., S.A.P., P.L.Z.), Hematology Unit, Centro Trapianti e Terapie Cellulari Carlo Melzi, Dipartimento di Science Mediche Sperimentali e Cliniche, Azienda Ospedaliero Universitaria, Udine (F.Z.), the Department of Cellular Biotechnologies and Hematology, Division of Hematology, Sapienza University, Rome (A.P., R.F.), the Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Regionale San Carlo, Potenza (M.C.), the Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara (D.R.), Hematology Unit, Ospedale Ferrarotto, Catania (G.M.), the Department of Onco-Hematology, Fondazione IRCCS, Policlinico San Matteo, Pavia (M.V.), Hematology Unit, Spedali Civili, Brescia (A. Anastasia), the Department of Medicine, Section of Hematology, University of Verona, Verona (A. Ambrosetti), Onco-Hematology Unit, Fondazione di Ricerca e Cura S.S. Giovanni Paolo II, Campobasso (V.F.), Institute of Hematology 1, IRCCS, Azienda Ospedaliero Universitaria San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genoa (A.M.C.), the Department of Hematology, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona (P.L.), and the Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo (A.R.) - all in Italy; Leukemia Service (J.H.P., S.S.C., R.L.L., O.A-W., M.S.T.,) and Dermatology Service (M.E.L.), the Department of Medicine, Human Oncology and Pathogenesis Program (S.S., Y.R.C., E.K., R.L.L., C.Y.P., M.F.B., O.A-W.), the Departments of Epidemiology and Biostatistics (S.D.), Pathology (C.Y.P.), and Pharmaco

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1506583DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811324PMC
October 2015

BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.

Cancer Cell 2015 Sep 3;28(3):370-83. Epub 2015 Sep 3.

Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Center for Mechanism Based Therapeutics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2015.08.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894664PMC
September 2015

A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.

Oncologist 2015 Jul 8;20(7):789-97. Epub 2015 May 8.

Departments of Medicine and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, New York, USA; Human Oncology and Pathogenesis Program, Memorial Hospital Research Laboratories, New York, New York, USA; Immunology and Molecular and Pharmacology and Chemistry Programs, Sloan Kettering Institute, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492223PMC
July 2015

Therapy-induced tumour secretomes promote resistance and tumour progression.

Nature 2015 Apr 25;520(7547):368-72. Epub 2015 Mar 25.

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature14336DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507807PMC
April 2015

PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer.

Sci Transl Med 2015 Apr;7(283):283ra51

Human Oncology and Pathogenesis Program and Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 20, New York, NY 10065, USA. Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aaa4442DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433148PMC
April 2015

Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.

Cancer Discov 2015 Jan 16;5(1):64-71. Epub 2014 Oct 16.

Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-0742DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705028PMC
January 2015

SOS1 and Ras regulate epithelial tight junction formation in the human airway through EMP1.

EMBO Rep 2015 Jan 13;16(1):87-96. Epub 2014 Nov 13.

Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15252/embr.201439218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4304732PMC
January 2015

Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ.

Cancer Cell 2015 Jan 24;27(1):109-22. Epub 2014 Dec 24.

Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2014.11.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293347PMC
January 2015

Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.

Cancer Cell 2014 Nov 10;26(5):603-4. Epub 2014 Nov 10.

Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108140042
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2014.10.017DOI Listing
November 2014

PTEN is a protein tyrosine phosphatase for IRS1.

Nat Struct Mol Biol 2014 Jun 11;21(6):522-7. Epub 2014 May 11.

Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nsmb.2828DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4167033PMC
June 2014

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.

Cancer Discov 2014 May 3;4(5):538-45. Epub 2014 Mar 3.

1Human Oncology and Pathogenesis Program, 2Leukemia Service, 3Gastrointestinal Oncology Service, 4Melanoma and Immunotherapeutics Service, Department of Medicine, 5Molecular Diagnostics Service, Department of Pathology, 6Department of Radiology, 7Center for Molecular Oncology, 8Ludwig Center for Cancer Immunotherapy, and 9Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center; and 10Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-1038DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850735PMC
May 2014

PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.

Clin Cancer Res 2014 May 14;20(9):2326-37. Epub 2014 Mar 14.

Authors' Affiliations: Breast Service, Department of Surgery; Departments of Pathology; and Medicine; and the Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2267DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4015460PMC
May 2014

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

Cancer Cell 2014 May 17;25(5):697-710. Epub 2014 Apr 17.

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2014.03.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049532PMC
May 2014

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Cancer Res 2014 Apr 27;74(8):2340-50. Epub 2014 Feb 27.

Authors' Affiliations: Louis V. Gerstner, Jr. Graduate School of Biomedical Science; Human Oncology and Pathogenesis Program; Departments of Pediatrics, Pathology, and Medicine; Programs in Molecular Pharmacology and Chemistry; Computational Biology; Ludwig Collaborative Lab, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles; Departments of Epidemiology and Biostatistics and Medicine, and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-2625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005042PMC
April 2014

Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.

Cancer Discov 2014 Mar 16;4(3):334-47. Epub 2014 Jan 16.

1Program in Molecular Pharmacology; 2Human Oncology and Pathogenesis Program; 3Program in Cell Biology, Memorial Sloan-Kettering Cancer Center; 4Weill Cornell Medical College, New York, New York; and 5Bayer HealthCare, Global Drug Discovery, Berlin, Germany.

View Article

Download full-text PDF

Source
http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-13-0611DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4049524PMC
March 2014

Towards a unified model of RAF inhibitor resistance.

Cancer Discov 2014 Jan;4(1):27-30

1Department of Medicine, 2Human Oncology and Pathogenesis Program, and 3Program in Molecular Pharmacology, Memorial Sloan-Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0961DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986142PMC
January 2014

Tumor adaptation and resistance to RAF inhibitors.

Nat Med 2013 Nov;19(11):1401-9

1] Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. [2] Program in Molecular Pharmacology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm.3392DOI Listing
November 2013

ERK pathway inhibitors: how low should we go?

Cancer Discov 2013 Jul;3(7):719-21

Louis V. Gerstner, Jr. Sloan-Kettering Graduate School of Biomedical Sciences, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0245DOI Listing
July 2013

Progression of RAS-mutant leukemia during RAF inhibitor treatment.

N Engl J Med 2012 Dec 7;367(24):2316-21. Epub 2012 Nov 7.

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1208958DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627494PMC
December 2012

Inhibition of mycobacterial infection by the tumor suppressor PTEN.

J Biol Chem 2012 Jun 21;287(27):23196-202. Epub 2012 May 21.

Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M112.351940DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391101PMC
June 2012

Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?

J Clin Oncol 2012 Jan 7;30(3):329-30. Epub 2011 Nov 7.

Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.38.2895DOI Listing
January 2012

mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.

Cancer Discov 2011 Aug 17;1(3):248-59. Epub 2011 Jun 17.

Program in Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-11-0085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227125PMC
August 2011

Resistance to BRAF inhibition in melanomas.

N Engl J Med 2011 Feb;364(8):772-4

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMcibr1013704DOI Listing
February 2011

Mutant BRAF melanomas--dependence and resistance.

Cancer Cell 2011 Jan;19(1):11-5

Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, NY, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2011.01.008DOI Listing
January 2011

Oncogenic RAF: a brief history of time.

Pigment Cell Melanoma Res 2010 Dec;23(6):760-2

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1755-148X.2010.00779.x
Publisher Site
http://dx.doi.org/10.1111/j.1755-148X.2010.00779.xDOI Listing
December 2010

PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.

Cancer Res 2010 Sep 10;70(17):6804-14. Epub 2010 Aug 10.

Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-0409DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178450PMC
September 2010

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Nature 2010 Mar;464(7287):427-30

Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature08902DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178447PMC
March 2010

Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.

Magn Reson Med 2009 Nov;62(5):1112-9

Department of Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/mrm.22137
Publisher Site
http://dx.doi.org/10.1002/mrm.22137DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859036PMC
November 2009

Phosphorylated 4E-BP1 is associated with poor survival in melanoma.

Clin Cancer Res 2009 Apr 31;15(8):2872-8. Epub 2009 Mar 31.

Department of Dermatology, New York University School of Medicine, New York, NY 10016, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-2336DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995540PMC
April 2009

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.

Proc Natl Acad Sci U S A 2009 Mar 27;106(11):4519-24. Epub 2009 Feb 27.

Department of Pediatrics, Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0900780106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2649208PMC
March 2009

Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.

Cancer Res 2009 Feb 27;69(3):958-66. Epub 2009 Jan 27.

David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-2216DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219545PMC
February 2009